Skip to main content

Table 1 Cohort demographics and disease characteristics

From: Visualization of atherosclerosis as detected by coronary artery calcium and carotid intima-media thickness reveals significant atherosclerosis in a cross-sectional study of psoriasis patients in a tertiary care center

Demographics Psoriasis (N = 207) Controls (N = 76) p-value
Mean ± SEM or N (%) Mean ± SEM or N (%)
Age (years) 47.8 ± 1.0 48.8 ± 2.0 0.651
Gender (male) 114 (55.1 %) 40 (52.6 %) 0.715
Race (not Caucasian) 24 (11.6 %) 9 (11.8 %) 0.954
Characteristics of interest
BMI (kg/m2) 30.9 ± 0.5 28.9 ± 0.1 0.025
Current smoker 78 (37.7 %) 14 (18.4 %) 0.002
Dyslipidemia 110 (53.1 %) 28 (36.8 %) 0.022
Systolic blood pressure 131 ± 1.3 123 ± 2.2 0.002
Fasting blood glucose (mg/dL) 94.7 ± 1.7 91.6 ± 1.4 0.184
HDL (mg/dL) 51.1 ± 1.0 55.9 ± 1.5 0.009
Hypertension 95 (45.9 %) 19 (25.0 %) 0.001
hsCRP 5.6 ± 0.7 3.3 ± 1.0 0.003
LDL (mg/dL) 121.2 ± 2.5 110.4 ± 3.9 0.027
Statin therapy 44 (21.3 %) 16 (21.1 %) 0.97
Total cholesterol (mg/dL) 197.4 ± 3.0 188.9 ± 4.7 0.128
Triglyceride (mg/dL) 125.9 ± 5.4 115.2 ± 11.3 0.392
Waist circumference (in) 40.2 ± 0.5 38.4 ± 0.6 0.028
Coronary artery calcium (CAC) 159 ± 32 130 ± 52 0.649
10 year Framingham risk score 5.8 ± 0.4 4.8 ± 0.8 0.235
Psoriasis specific
BSA 14.3 ± 1.3 N/A ND
PASI 10 ± 0.7 N/A ND
PGA 2.2 ± 0.1 N/A ND
Psoriasis arthritis 51 (24.6 %) N/A ND
Psoriasis duration (years) 19.4 ± 1.0 N/A ND
Psoriasis treatment(s)
Biologics 49 (23.7 %) N/A ND
Cyclosporine 5 (2.4 %) N/A ND
Methotrexate 13 (6.3 %) N/A ND
Narrow band UVB 13 (6.3 %) N/A ND
Oral retinoids 7 (3.4 %) N/A ND
Topicals 96 (46.4 %) N/A ND